IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2003;44:974-979.)
© 2003 by The Association for Research in Vision and Ophthalmology, Inc.
DOI:  10.1167/iovs.02-0392
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wilkinson-Berka, J. L.
Right arrow Articles by Gilbert, R. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilkinson-Berka, J. L.
Right arrow Articles by Gilbert, R. E.

COX-2 Inhibition and Retinal Angiogenesis in a Mouse Model of Retinopathy of Prematurity

Jennifer L. Wilkinson-Berka,1 Nicole S. Alousis,1 Darren J. Kelly,2 and Richard E. Gilbert2

1From the Department of Physiology, University of Melbourne, Parkville, Victoria, Australia; and the 2Department of Medicine, St. Vincent’s Hospital, Fitzroy, Queensland, Australia.

PURPOSE. The prostaglandin-cyclooxygenase (COX) pathway influences new blood vessel growth in a variety of tissues. This study was conducted to determine the cellular location of COX-2 in the retina and whether the inhibition of COX-2 would reduce retinal angiogenesis in a rodent model of retinopathy of prematurity (ROP).

METHODS. ROP was induced in C57BL/6 mice by exposing 7-day-old mice to 75% oxygen (hyperoxia) for 5 days followed by 5 days in room air (relative hypoxia and retinal angiogenesis). Normal mice were those with a normally developing retinal vasculature exposed to room air from birth until postnatal day (P)17. The COX-2 inhibitor, rofecoxib (15 mg/kg body weight intraperitoneally) was administered to normal and ROP mice from P12 to P17. Immunohistochemistry for COX-2 was performed on retinas from all groups by the avidin-biotin method. Histologic methods were used to count blood vessel profiles (BVPs) in the inner retina (inner limiting membrane, ganglion cell layer, and inner plexiform layer) with a masked approach.

RESULTS. Intense COX-2 immunolabeling was specifically localized to ganglion cells and blood vessels of all mice retinas. In ROP mice, COX-2 immunolabeling was detected on blood vessels extending into the vitreous cavity. Quantitation of BVPs in the inner retina revealed an increase in untreated ROP mice compared with untreated normal mice (P < 0.001). Rofecoxib decreased BVPs by approximately 45% in normal mice and 37% in ROP mice.

CONCLUSIONS. COX-2 is localized to sites associated with retinal blood vessels. The finding that the selective COX-2 inhibitor, rofecoxib, attenuated the retinal angiogenesis that accompanies ROP, and normal retinal development indicates that COX-2 plays an important role in blood vessel formation in the retina.




This article has been cited by other articles:


Home page
 Br. J. Ophthalmol.Home page
A M A. El-Asrar, L Missotten, and K Geboes
Expression of cyclo-oxygenase-2 and downstream enzymes in diabetic fibrovascular epiretinal membranes
Br. J. Ophthalmol., November 1, 2008; 92(11): 1534 - 1539.
[Abstract] [Full Text] [PDF]

Home page
 Arch OphthalmolHome page
D. Navaratna, J. Maestas, P. G. McGuire, and A. Das
Suppression of Retinal Neovascularization With an Antagonist to Vascular Endothelial Cadherin
Arch Ophthalmol, August 1, 2008; 126(8): 1082 - 1088.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
S. Schwartz, J. George, J. Ben-Shoshan, G. Luboshits, I. Avni, H. Levkovitch-Verbin, H. Ziv, M. Rosner, and A. Barak
Drug Modification of Angiogenesis in a Rat Cornea Model
Invest. Ophthalmol. Vis. Sci., January 1, 2008; 49(1): 250 - 254.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
J. L. Wilkinson-Berka, D. Jones, G. Taylor, K. Jaworski, D. J. Kelly, S. B. Ludbrook, R. N. Willette, S. Kumar, and R. E. Gilbert
SB-267268, a Nonpeptidic Antagonist of {alpha}v{beta}3 and {alpha}v{beta}5 Integrins, Reduces Angiogenesis and VEGF Expression in a Mouse Model of Retinopathy of Prematurity.
Invest. Ophthalmol. Vis. Sci., April 1, 2006; 47(4): 1600 - 1605.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
P. van Wijngaarden, D. J. Coster, H. M. Brereton, I. L. Gibbins, and K. A. Williams
Strain-Dependent Differences in Oxygen-Induced Retinopathy in the Inbred Rat
Invest. Ophthalmol. Vis. Sci., April 1, 2005; 46(4): 1445 - 1452.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
T. A. Gardiner, D. S. Gibson, T. E. de Gooyer, V. F. de la Cruz, D. M. McDonald, and A. W. Stitt
Inhibition of Tumor Necrosis Factor-{alpha} Improves Physiological Angiogenesis and Reduces Pathological Neovascularization in Ischemic Retinopathy
Am. J. Pathol., February 1, 2005; 166(2): 637 - 644.
[Abstract] [Full Text] [PDF]

Home page
 IOVSHome page
A. J. Franklin, T. L. Jetton, C. L. Kuchemann, S. R. Russell, and E. C. Kohn
CAI Is a Potent Inhibitor of Neovascularization and Imparts Neuroprotection in a Mouse Model of Ischemic Retinopathy
Invest. Ophthalmol. Vis. Sci., October 1, 2004; 45(10): 3756 - 3766.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. L. Wilkinson-Berka, S. Babic, T. de Gooyer, A. W. Stitt, K. Jaworski, L. G. T. Ong, D. J. Kelly, and R. E. Gilbert
Inhibition of Platelet-Derived Growth Factor Promotes Pericyte Loss and Angiogenesis in Ischemic Retinopathy
Am. J. Pathol., April 1, 2004; 164(4): 1263 - 1273.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by the Association for Research in Vision and Ophthalmology